Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SSRIs not cause of birth defects

Executive Summary

No significant association between use of selective serotonin-reuptake inhibitors in early pregnancy and congenital heart defects or most other birth defects was detected in a pair of case-control surveillance studies published in the June 28 issue of the New England Journal of Medicine. Results from the Slone Epidemiology Center Birth Defects Study found no significant increases in certain birth defects for the antidepressant class, but the findings "suggest that individual SSRIs may confer increased risks for some specific defects," although "the absolute risks are small." The Slone study found an association between sertraline (Pfizer's Zoloft and generics) and omphalocele and septal defects and between paroxetine (GlaxoSmithKline's Paxil and generics) and right ventricular outflow obstruction defects. Language regarding congenital malformations was added to Paxil labeling in 2005, and GSK is conducting its own epidemiologic studies examining the potential for birth defects (1"The Pink Sheet" Oct. 3, 2005, p. 10)...

You may also be interested in...



Paxil CR Labeling Adds New Data On Birth Defects; GSK Plans Further Studies

GlaxoSmithKline is conducting additional epidemiologic studies to better understand preliminary data suggesting a potential link between paroxetine use and birth defects, the company said in a "Dear Doctor" letter on revised labeling for Paxil CR and Paxil

Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand

Cipla has expanded its partnership with Alvotech to cover the commercialization of five biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.

No Eudamed, No Problem! Latest Guidance Explains Alternatives While Database Is Built

Lack of official explanation about how the exchange of critical information will progress pending the launch of the EU’s medical device database, Eudamed3, has left many confused. New guidance lights the way forward.

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel